The birth weight lowering C-allele of rs900400 near LEKR1 and CCNL1 associates with elevated insulin release following an oral glucose challenge.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3208566)

Published in PLoS One on November 04, 2011

Authors

Ehm A Andersson1, Marie N Harder, Kasper Pilgaard, Charlotta Pisinger, Alena Stančáková, Johanna Kuusisto, Niels Grarup, Kristine Færch, Pernille Poulsen, Daniel R Witte, Torben Jørgensen, Allan Vaag, Markku Laakso, Oluf Pedersen, Torben Hansen

Author Affiliations

1: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Associated clinical trials:

Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease | NCT00289237

Articles cited by this

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28

The thrifty phenotype hypothesis. Br Med Bull (2001) 7.98

A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil (2003) 4.25

The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet (1999) 3.48

Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes (2007) 3.25

Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care (2003) 2.96

Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol (2007) 2.68

Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet (2010) 2.30

Type 2 diabetes risk alleles are associated with reduced size at birth. Diabetes (2009) 1.58

Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. Am J Hum Genet (2007) 1.52

Examination of type 2 diabetes loci implicates CDKAL1 as a birth weight gene. Diabetes (2009) 1.34

Type 2 diabetes risk alleles near ADCY5, CDKAL1 and HHEX-IDE are associated with reduced birthweight. Diabetologia (2010) 1.28

Low birthweight and premature birth are both associated with type 2 diabetes in a random sample of middle-aged Danes. Diabetologia (2010) 1.11

Obesity-susceptibility loci have a limited influence on birth weight: a meta-analysis of up to 28,219 individuals. Am J Clin Nutr (2011) 1.10

Interaction between prenatal growth and high-risk genotypes in the development of type 2 diabetes. Diabetologia (2009) 1.07

Impact of size at birth and prematurity on adult anthropometry in 4744 middle-aged Danes - The Inter99 study. J Dev Orig Health Dis (2010) 0.85

HNF1A mutation presenting with fetal macrosomia and hypoglycemia in childhood prior to onset of overt diabetes. J Pediatr Endocrinol Metab (2011) 0.79

Articles by these authors

A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 43.63

Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06

Enterotypes of the human gut microbiome. Nature (2011) 24.36

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet (2005) 21.91

Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med (2003) 20.06

Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16

Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med (2008) 18.27

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96

Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

Many sequence variants affecting diversity of adult human height. Nat Genet (2008) 12.80

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65

Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44

Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet (2008) 12.43

A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68

Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09

Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48

SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet (2008) 8.63

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

Vascular risk factors and diabetic neuropathy. N Engl J Med (2005) 7.69

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Richness of human gut microbiome correlates with metabolic markers. Nature (2013) 6.93

The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88

Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. PLoS Genet (2009) 5.81

A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet (2008) 5.49

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation (2002) 5.45

Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44